Christopher A. Kroeger - 27 Oct 2025 Form 4 Insider Report for MapLight Therapeutics, Inc. (MPLT)

Role: Chief Executive Officer, Director
Signature: /s/ Kristopher L. Hanson, Attorney-in-Fact
Issuer symbol: MPLT
Transactions as of: 27 Oct 2025
Net transactions value: $0
Form type: 4
Filing time: 28 Oct 2025, 16:15:10 UTC
Previous filing: 27 Oct 2025
Next filing: 29 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kroeger Christopher A.	Chief Executive Officer, Director	C/O MAPLIGHT THERAPEUTICS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY	/s/ Kristopher L. Hanson, Attorney-in-Fact	28 Oct 2025	0001658918

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MPLT	Voting Common Stock	Award	$0	+225,693		$0.000000	225,693	27 Oct 2025	Direct	F1, F2
transaction	MPLT	Voting Common Stock	Conversion of derivative security		+3,895	+1.7%		229,588	28 Oct 2025	Direct	F3
holding	MPLT	Voting Common Stock						101,190	27 Oct 2025	See footnote	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MPLT	Employee Stock Option (right to buy)	Award	$0	+916,164		$0.000000	916,164	27 Oct 2025	Voting Common Stock	916,164	$17.00	Direct	F5
transaction	MPLT	Series C Preferred Stock	Conversion of derivative security	$0	-65,477	-100%	$0.000000	0	28 Oct 2025	Voting Common Stock	3,895		Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
F2	Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3	The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's IPO for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
F4	The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
F5	1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.